Home Cart 0 Sign in  

[ CAS No. 90604-02-7 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 90604-02-7
Chemical Structure| 90604-02-7
Structure of 90604-02-7 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 90604-02-7 ]

Related Doc. of [ 90604-02-7 ]

Alternatived Products of [ 90604-02-7 ]

Product Details of [ 90604-02-7 ]

CAS No. :90604-02-7 MDL No. :MFCD00209447
Formula : C16H18ClNO Boiling Point : -
Linear Structure Formula :- InChI Key :LCHTWRWPHBRTNO-UHFFFAOYSA-N
M.W : 275.77 Pubchem ID :2801726
Synonyms :

Calculated chemistry of [ 90604-02-7 ]

Physicochemical Properties

Num. heavy atoms : 19
Num. arom. heavy atoms : 12
Fraction Csp3 : 0.25
Num. rotatable bonds : 3
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 83.14
TPSA : 23.47 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.56 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.0
Log Po/w (XLOGP3) : 3.41
Log Po/w (WLOGP) : 2.55
Log Po/w (MLOGP) : 2.77
Log Po/w (SILICOS-IT) : 2.8
Consensus Log Po/w : 2.3

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.97
Solubility : 0.0297 mg/ml ; 0.000108 mol/l
Class : Soluble
Log S (Ali) : -3.58
Solubility : 0.0721 mg/ml ; 0.000261 mol/l
Class : Soluble
Log S (SILICOS-IT) : -4.33
Solubility : 0.0129 mg/ml ; 0.0000468 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 0.0
Synthetic accessibility : 2.28

Safety of [ 90604-02-7 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 90604-02-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 90604-02-7 ]
  • Downstream synthetic route of [ 90604-02-7 ]

[ 90604-02-7 ] Synthesis Path-Upstream   1~12

  • 1
  • [ 90604-02-7 ]
  • [ 40320-60-3 ]
YieldReaction ConditionsOperation in experiment
82% With sulfur trioxide pyridine complex; triethylamine In dimethyl sulfoxide at 0 - 20℃; To a solution of pyridine sulfur trioxide (29.95 g, 188 mmol) in DMSO (100 mL) at 0° C., was added triethylamine (26.2 mL) and C48 (15.0 g, 62.7 mmol) in DMSO (50 mL).
The mixture was warmed to room temperature after 5 mins and stirred for 3 h.
The reaction was quenched with saturated aqueous sodium chloride solution and extracted with EtOH; the organic layer was washed with a saturated aqueous solution of sodium bicarbonate, saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and evaporated.
The residue was purified by silica gel chromatography (Eluant: 1:1:100:200 MeOH: triethylamine: EtOAc: hexane) to afford C74 as a yellow solid. Yield: 12.2 g, 51.4 mmol, 82percent. 1H NMR (400 MHz, CDCl3) δ4.02 (s, 4H), 4.61 (s, 1H), 7.23 (m, 2H), 7.32 (m, 4H), 7.49 (m, 4H).
66% With sulfur trioxide pyridine complex; triethylamine In dimethylsulfoxide-d6 for 2 h; Example 95-amino-I -(I -cyanoazetidi n-3-yl)-3-(4-phenoxyphenyl)-I H-pyrazole-4-carboxamide Step i: preparation of i-(diphenylmethyl)azetidin-3-one. To a stirred solution of sulfur trioxide-pyridine complex (69 g, 432.95 mmol) in dimethylsulfoxide (i 72.6 mL) was added a solution of i-(diphenylmethyl)azetidin-3-ol hydrochloric acid (20 g, 72.52 mmol) and triethylamine (50.5 mL, 362.6 mmol) in tetrahydrofuran (69 mL) drop wise over 10 minutes. The solution was allowed to stir for 2h. The reaction mixture was then poured into water and extracted into 50percent ethyl acetate hexanes. The organic layers were combined and washed with brine, dried over sodium sulfate, and concentrated invacuo to afford the title compound (11.4 g, 66percent).
43.2% at 20 - 50℃; for 0.5 h; (Production Example 78) 1-Benzhydrylazetidin-3-one
To a mixture of 1-benzhydrylazetidin-3-ol hydrochloride (5.52 g) and triethylamine (27.9 ml) was added dropwise a solution of pyridine sulfur trioxide complex (19.7 g) in dimethyl sulfoxide (80 ml) at room temperature.
The reaction mixture was stirred at 50 °C for 30 min.
The reaction was allowed to cool down to room temperature.
This was poured into ice water.
This was extracted with ethyl acetate, and the organic layer was washed with brine.
Activated carbon (5 g) was added to the organic layer, followed by stirring at room temperature for 3 days.
Activated carbon was removed by filtration and the filtrate was concentrated.
The residue was dissolved in methanol (200 ml), and activated carbon (10 g) was added thereto, followed by stirring at room temperature for 3 days.
Activated carbon was removed by filtration, and the filtrate was concentrated.
The residue was purified by silica gel column chromatography (eluent; heptane:ethyl acetate = 4:1, then 2:1).
Fractions containing the target compound were concentrated to provide the target compound as a pale yellow oil (3.21 g).
Hexane was added thereto to precipitate crystals, which were collected by filtration.
Drying under aeration provided the titled compound (1.11 g, 23.4 percent).
To the residue obtained by concentrating the filtrate was added hexane, and allowed to stand at room temperature.
After crystals precipitated, supernatant was removed by a pipette.
This was dried under reduced pressure to provide the titled compound as pale yellow crystals (940 mg, 19.8 percent).
1H-NMR Spectrum (CDCl3) δ (ppm): 4.01 (4H, s), 4.60 (1H, s), 7.22 (2H, m), 7.30 (4H, m), 7.48 (4H, m).
37% With 4-methyl-morpholine; tetrapropylammonium perruthennate; 4-methylmorpholine N-oxide In dichloromethane at 0 - 20℃; for 24 h; Molecular sieve l-(Diphenylmethyl)azetidin-3-ol hydrochloride (2.75 g, 9.98 mmol), prepared using procedures similar to those described for Scheme 1 of the General Synthetic Section, 3 A molecular sieves and 4-methylmorpholine (1.1 niL, 10.0 mmol) were suspended in dichloromethane (20 mL) at 0 0C. 4-Methylmorpholine N-oxide (2.93 g, 25.0 mmol) and tetrapropylammonium perruthenate (140 mg, 0.399 mmol) were added and the mixture was stirred at ambient for 24 h. The mixture was filtered through a plug of silica using 5percent triethylamine in ethyl acetate as eluent. The filtrate was concentrated in vacuo and the residue was partitioned between ethyl acetate and saturated sodium bicarbonate solution. The organic portion was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. Column chromatography (silica gel, 8:1 hexanes:ethyl acetate) gave l-(diphenylmethyl)azetidin-3-one (871 mg, 3.68 mmol, 37percent yield): 1H NMR (400 MHz, CDCl3): 7.50-7.46 (m, 4H), 7.33-7.27 (m, 4H), 7.27-7.19 (m, 2H), 4.59 (s, IH), 4.01 (s, 4H); MS (EI) for CJ6H15NO: 238 (MH+).
37% With 4-methyl-morpholine; tetrapropylammonium perruthennate; 4-methylmorpholine N-oxide In dichloromethane at 0 - 20℃; for 24 h; Molecular sieve l-(Diphenylmethyl)azetidin-3-ol hydrochloride (2.75 g, 9.98 mmol), prepared using procedures similar to those described for Scheme 1 of the General Synthetic Section, 3 A molecular sieves and 4-methylmorpholine (1.1 mL, 10.0 mmol) were suspended in dichloromethane (20 mL) at 0 0C. 4-Methylmorpholine N-oxide (2.93 g, 25.0 mmol) and tetrapropylammonium perruthenate (140 mg, 0.399 mmol) were added and the mixture was stirred at ambient for 24 h. The mixture was filtered through a plug of silica using 5percent triethylamine in ethyl acetate as eluent. The filtrate was concentrated in vacuo and the residue was partitioned between ethyl acetate and saturated sodium bicarbonate solution. The organic portion was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. Column chromatography (silica gel, 8:1 hexanes:ethyl acetate) gave 1- (diphenylmethyl)azetidin-3-one (871 mg, 3.68 mmol, 37percent yield): 1H NMR (400 MHz, CDCl3): 7.50-7.46 (m, 4H), 7.33-7.27 (m, 4H), 7.27-7.19 (m, 2H), 4.59 (s, IH), 4.01 (s, 4H); MS (EI) for C16H15NO: 238 (MH+).
37% With 4-methyl-morpholine; tetrapropylammonium perruthennate; 4-methylmorpholine N-oxide In dichloromethane at 0 - 20℃; for 24 h; 3A molecular sieves l-(Diphenylmethyl)azetidin-3-ol hydrochloride (2.75 g, 9.98 mmol), prepared using procedures similar to those described for Scheme 1 of the General Synthetic Section, 3 A molecular sieves and 4-methylmorpholine (1.1 mL, 10.0 mmol) were suspended in dichloromethane (20 mL) at 0 0C. 4-Methylmorpholine N-oxide (2.93 g, 25.0 mmol) and tetrapropylammonium perruthenate (140 mg, 0.399 mmol) were added and the mixture was stirred at ambient for 24 h. The mixture was filtered through a plug of silica using 5percent triethylamine in ethyl acetate as eluent. The filtrate was concentrated in vacuo and the residue was partitioned between ethyl acetate and saturated sodium bicarbonate solution. The organic portion was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. Column chromatography (silica gel, 8:1 hexanes:ethyl acetate) gave l-(diphenylmethyl)azetidin-3-one (871 mg, 3.68 mmol, 37percent yield): 1H NMR (400 MHz, CDCl3): 7.50-7.46 (m, 4H), 7.33-7.27 (m, 4H), 7.27-7.19 (m, 2H), 4.59 (s, IH), 4.01 (s, 4H); MS (EI) for C16H15NO: 238 (MH+).
19.8% With pyridine-SO3 complex; triethylamine In dimethyl sulfoxide at 20 - 50℃; for 0.5 h; A solution of pyridine sulfur trioxide complex (19.7 g) in dimethyl sulfoxide (80 ml) was added dropwise to a mixture of 1-benzhydrylazetidin-3-ol hydrochloride (5.52 g) and triethylamine (27.9 ml) at room temperature. The reaction mixture was stirred at 50° C. for 30 minutes. The reaction mixture was allowed to cool down to room temperature, and poured into ice water. This was extracted with ethyl acetate, and the organic layer was washed with brine. Activated carbon (5 g) was added to the organic layer, followed by stirring at room temperature for 3 days. The activated carbon was removed by filtration, and the filtrate was concentrated. The residue was dissolved in methanol (200 ml), and activated carbon (10 g) was added thereto, followed by stirring at room temperature for 3 days. The activated carbon was removed by filtration, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (eluent; heptane:ethyl acetate=4:1, then 2:1). The fractions containing the target compound were concentrated to give the target compound (3.21 g) as a pale yellow oil. Hexane was added thereto to precipitate crystals, and the crystals were collected by filtration. Drying under aeration gave the title compound (1.11 g, 23.4percent) as white crystals. Hexane was added to the residue obtained by concentration of the filtrate, which was allowed to stand at room temperature. After crystals precipitated, the supernatant was removed using a pipette. These were dried under reduced pressure to give the title compound (940 mg, 19.8percent) as pale yellow crystals.1H-NMR Spectrum (CDCl3) δ (ppm): 4.01 (4H, s), 4.60 (1H, s), 7.22 (2H, m), 7.30 (4H, m), 7.48 (4H, m).

Reference: [1] Patent: US2010/190771, 2010, A1, . Location in patent: Page/Page column 38
[2] Journal of Medicinal Chemistry, 2017, vol. 60, # 16, p. 7029 - 7042
[3] Patent: WO2014/68527, 2014, A1, . Location in patent: Page/Page column 83; 84
[4] Chemistry Letters, 1999, # 7, p. 605 - 606
[5] Patent: EP1889836, 2008, A1, . Location in patent: Page/Page column 78
[6] Patent: WO2007/44515, 2007, A1, . Location in patent: Page/Page column 213
[7] Patent: WO2008/76415, 2008, A1, . Location in patent: Page/Page column 383
[8] Patent: WO2008/124085, 2008, A2, . Location in patent: Page/Page column 231
[9] ACS Medicinal Chemistry Letters, 2012, vol. 3, # 5, p. 416 - 421
[10] Patent: US2008/214815, 2008, A1, . Location in patent: Page/Page column 12-13
  • 2
  • [ 79-37-8 ]
  • [ 90604-02-7 ]
  • [ 40320-60-3 ]
Reference: [1] Patent: US6291457, 2001, B1,
  • 3
  • [ 90604-02-7 ]
  • [ 18621-17-5 ]
Reference: [1] Patent: US2009/233903, 2009, A1, . Location in patent: Page/Page column 62
[2] Patent: US2014/256941, 2014, A1, . Location in patent: Paragraph 0155
  • 4
  • [ 124-63-0 ]
  • [ 90604-02-7 ]
  • [ 33301-41-6 ]
YieldReaction ConditionsOperation in experiment
91% With triethylamine In dichloromethane at 0 - 20℃; C.
Preparation of 1-(diphenylmethyl)azetidin-3-yl methanesulfonate (C49).
Methanesulfonyl chloride (180 g, 1.57 mol) was added to a solution of C48 (360 g, 1.31 mol) and triethylamine (330 g, 3.26 mol) in dichloromethane (3 L) at 0° C.
The reaction mixture was stirred at room temperature for 3 h, quenched with saturated aqueous sodium bicarbonate solution, then extracted with dichloromethane.
The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford C49. Yield: 360 g, 1.14 mol, 87percent.
B. Preparation of 1-(diphenylmethyl)azetidin-3-yl methanesulfonate (C49). Compound C49 was prepared according to the procedure described in Preparation 1 to afford C49 as a yellow solid. Yield: 303 g, 0.96 mol, 91percent. 1H NMR (400 MHz, CDCl3) δ 2.91 (s, 3H), 3.13 (m, 2H), 3.55 (m, 2H), 4.31 (s, 1H), 4.02 (m, 1H), 7.14 (m, 2H), 7.20 (m, 4H), 7.31 (m, 4H).
Reference: [1] Patent: US2010/190771, 2010, A1, . Location in patent: Page/Page column 28-29
[2] Journal of Medicinal Chemistry, 2012, vol. 55, # 21, p. 9055 - 9068
  • 5
  • [ 90604-02-7 ]
  • [ 18621-18-6 ]
YieldReaction ConditionsOperation in experiment
94% With hydrogen In ethanol at 20℃; for 12 h; A solution of l-(diphenylmethyl)-3-hydroxyazetidine hydrochloride (11.8 g) in absolute ethanol (700 mL) was hydrogenated at room temperature over Pd(OH)2/C in a Parr shaker at 4 atm. After 12 hr the catalyst was filtered off and the filtrate evaporated to dryness to give3-hydroxyazetidine hydrochloride (4.20 g, 94percent). 1H-NMR (300 MHz, DMSO-de, ppm from TMS): δ 9.07 (2H, bb), 6.19 (IH, bb), 4.49 (IH, m), 3.99 (2H, m), 3.71 (2H, m).
52% With hydrogen In methanol for 48 h; A reaction mixture of N-benzhydrylazetidin-3-ol HCl salt (2.76 g, 10.0 mmol) with palladium hydroxide, 20percent Pd (dry base) on C (400 mg) in 50 mL of MeOH was hydrogenated at 55 psi for 48 h. The reaction mixture was filtered through Celite pad and washed well with MeOH. The filtrate was concentrated under vacuum at room temperature water bath. The residue was treated with ether (3x30 ml) and the solvent is decanted. The solid was air dried to give 571 mg of HCl salt product (2) as white solid (52percent yield). 1H NMR (400 MHz, DMSO-D6) δ ppm 3.33 (s, 1H) 3.63-3.80 (m, 2H) 3.93-4.09 (m, 2H) 4.40-4.58 (m, 1H) 6.18 (d, J=6.32 Hz, 1H).
52% With hydrogen In methanol for 48 h; A reaction mixture of N-benzhydrylazetidin-3-ol HCI salt (2.76 g, 10.0 mmol) with palladium hydroxide, 20percent Pd (dry base) on C (400 mg) in 50 mL of MeOH was hydrogenated at 55 psi for 48 h. The reaction mixture was filtered through Celite pad and washed well with MeOH. The filtrate was concentrated under vacuum at room temperature water bath. The residue was treated with ether (3x30ml) and the solvent is decanted. The solid was air dried to give 571 mg of HCI salt product (2-2) as white solid (52percent yield). 1H NMR (400 MHz, DMSO-D6) 5 ppm 3.33 (s, 1 H) 3.63 - 3.80 (m, 2 H) 3.93 -4.09 (m, 2 H) 4.40 - 4.58 (m, 1 H) 6.18 (d, J=6.32 Hz, 1 H).
Reference: [1] Journal of Antibiotics, 2006, vol. 59, # 4, p. 241 - 247
[2] Journal of Medicinal Chemistry, 2008, vol. 51, # 15, p. 4601 - 4608
[3] Patent: WO2007/118830, 2007, A1, . Location in patent: Page/Page column 91
[4] Patent: US2006/46991, 2006, A1, . Location in patent: Page/Page column 57-58
[5] Patent: WO2006/21881, 2006, A2, . Location in patent: Page/Page column 62; 63
[6] Heterocycles, 1992, vol. 33, # 2, p. 523 - 528
[7] Journal of Heterocyclic Chemistry, 1994, vol. 31, # 2, p. 271 - 276
  • 6
  • [ 18621-17-5 ]
  • [ 90604-02-7 ]
YieldReaction ConditionsOperation in experiment
100% With hydrogenchloride In ethyl acetate at 20℃; for 0.166667 h; 1-(Diphenylmethyl) -3 -hydroxy azetidine (9.70 g) was suspended in 4.5M HCl in EtOAc (35 niL) at room temperature and stirred for 10 min. The solvent was then evaporated to dryness to give l-(diphenylmethyl)- 3-hydroxyazetidine hydrochloride (12.0 g, 100percent). 1H-NMR (300 MHz, DMSO-de, ppm from TMS): δ 7.30-7.70 (1OH, m), 5.85 (IH, s), 5.80 (IH, d), 4.46 (IH, m), 3.70-4.20 (4H, m).
Reference: [1] Patent: WO2007/118830, 2007, A1, . Location in patent: Page/Page column 91
  • 7
  • [ 91-00-9 ]
  • [ 106-89-8 ]
  • [ 90604-02-7 ]
Reference: [1] Patent: US2003/28976, 2003, A1,
[2] Patent: US2004/132788, 2004, A1,
[3] Journal of Medicinal Chemistry, 1993, vol. 36, # 7, p. 801 - 810
[4] Heterocycles, 1992, vol. 33, # 2, p. 523 - 528
[5] Patent: US2009/233903, 2009, A1, . Location in patent: Page/Page column 62
[6] Patent: US2010/190771, 2010, A1, . Location in patent: Page/Page column 27-28
[7] Journal of Medicinal Chemistry, 2012, vol. 55, # 21, p. 9055 - 9068
[8] Patent: WO2013/36611, 2013, A1, . Location in patent: Page/Page column 26
[9] Patent: US2014/256941, 2014, A1, . Location in patent: Paragraph 0154
  • 8
  • [ 98-17-9 ]
  • [ 1643-19-2 ]
  • [ 124-63-0 ]
  • [ 91-00-9 ]
  • [ 106-89-8 ]
  • [ 90604-02-7 ]
Reference: [1] Patent: US5183902, 1993, A,
[2] Patent: US4956359, 1990, A,
[3] Patent: US5068231, 1991, A,
  • 9
  • [ 5267-34-5 ]
  • [ 106-89-8 ]
  • [ 90604-02-7 ]
Reference: [1] Chemistry Letters, 1999, # 7, p. 605 - 606
  • 10
  • [ 63477-43-0 ]
  • [ 90604-02-7 ]
Reference: [1] Journal of Antibiotics, 2006, vol. 59, # 4, p. 241 - 247
  • 11
  • [ 91-00-9 ]
  • [ 90604-02-7 ]
Reference: [1] Journal of Antibiotics, 2006, vol. 59, # 4, p. 241 - 247
  • 12
  • [ 24424-99-5 ]
  • [ 90604-02-7 ]
  • [ 141699-55-0 ]
YieldReaction ConditionsOperation in experiment
357 g
Stage #1: With sodium carbonate In dichloromethane; water at 20℃;
Stage #2: With palladium on carbon; hydrogen In tetrahydrofuran at 20℃; for 18 h;
Step 2. tert-Butyl 3-hydroxyazetidine-l -carboxylate (10) A suspension of l-benzhydrylazetidin-3-ol hydrochloride (9, 625 g, 2.27 mol) in a 10 percent solution of aqueous sodium carbonate (Na2C03, 5 L) and dichloromethane (CH2CI2, 5 L) was stirred at room temperature until all solids were dissolved. The two layers were separated, and the aqueous layer was extracted with dichloromethane (CH2CI2, 2 L). The combined organics extracts were dried over sodium sulfate (Na2SC>4) and concentrated under reduced pressure. This resulting crude free base of 9 was then dissolved in THF (6 L) and the solution was placed into a large Parr bomb. Di-teri-butyl dicarbonate (BOC20, 545 g, 2.5 mol, 1.1 equiv) and 20 percent palladium (Pd) on carbon (125 g, 50 percent wet) were added to the Parr bomb. The vessel was charged to 30 psi with hydrogen gas () and stirred under steady hydrogen atmosphere (vessel was recharged three times to maintain the pressure at 30 psi) at room temperature for 18 h. When HPLC showed that the reaction was complete (when no more hydrogen was taken up), the reaction mixture was filtered through a Celite pad and the Celite pad was washed with THF (4 L). The filtrates were concentrated under reduced pressure to remove the solvent and the residue was loaded onto a Biotage 150 column with a minimum amount of dichloromethane (CH2CI2). The column was eluted with 20 - 50 percent ethyl acetate in heptane and the fractions containing the pure desired product (10) were collected and combined. The solvents were removed under reduced pressure to afford terr-butyl 3-hydroxyazetidine-l - carboxylate (10, 357 g, 393.2 g theoretical, 90.8percent yield) as colorless oil, which solidified upon standing at room temperature in vacuum. For 10: 'iTNMR (CDCI3, 300 MHz), δ 4.56 (m 1 H), 4.13 (m, 2H), 3.81 (m, 2H), 1.43 (s, 9H) ppm.
Reference: [1] Patent: WO2013/36611, 2013, A1, . Location in patent: Page/Page column 27
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 90604-02-7 ]

Baricitinib Related Intermediates

Chemical Structure| 91-00-9

[ 91-00-9 ]

Diphenylmethanamine

Chemical Structure| 398489-26-4

[ 398489-26-4 ]

tert-Butyl 3-oxoazetidine-1-carboxylate

Chemical Structure| 1029716-44-6

[ 1029716-44-6 ]

1-(1-Ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

Chemical Structure| 141699-55-0

[ 141699-55-0 ]

tert-Butyl 3-hydroxyazetidine-1-carboxylate

Chemical Structure| 18621-17-5

[ 18621-17-5 ]

1-Benzhydrylazetidin-3-ol

Related Functional Groups of
[ 90604-02-7 ]

Aryls

Chemical Structure| 18621-17-5

[ 18621-17-5 ]

1-Benzhydrylazetidin-3-ol

Similarity: 0.98

Chemical Structure| 54881-13-9

[ 54881-13-9 ]

1-Benzylazetidin-3-ol

Similarity: 0.80

Chemical Structure| 1965305-27-4

[ 1965305-27-4 ]

1-Benzhydrylazetidin-3-amine hydrochloride

Similarity: 0.79

Chemical Structure| 82769-75-3

[ 82769-75-3 ]

(S)-3-(Dimethylamino)-3-phenylpropan-1-ol

Similarity: 0.79

Chemical Structure| 40320-60-3

[ 40320-60-3 ]

1-Benzhydrylazetidin-3-one

Similarity: 0.78

Alcohols

Chemical Structure| 18621-17-5

[ 18621-17-5 ]

1-Benzhydrylazetidin-3-ol

Similarity: 0.98

Chemical Structure| 54881-13-9

[ 54881-13-9 ]

1-Benzylazetidin-3-ol

Similarity: 0.80

Chemical Structure| 82769-75-3

[ 82769-75-3 ]

(S)-3-(Dimethylamino)-3-phenylpropan-1-ol

Similarity: 0.79

Chemical Structure| 1375303-15-3

[ 1375303-15-3 ]

2-(1-Benzhydrylazetidin-3-yl)propane-1,3-diol

Similarity: 0.77

Chemical Structure| 62855-02-1

[ 62855-02-1 ]

(R)-(1,2,3,4-Tetrahydroisoquinolin-3-yl)methanol

Similarity: 0.76

Related Parent Nucleus of
[ 90604-02-7 ]

Aliphatic Heterocycles

Chemical Structure| 18621-17-5

[ 18621-17-5 ]

1-Benzhydrylazetidin-3-ol

Similarity: 0.98

Chemical Structure| 54881-13-9

[ 54881-13-9 ]

1-Benzylazetidin-3-ol

Similarity: 0.80

Chemical Structure| 1965305-27-4

[ 1965305-27-4 ]

1-Benzhydrylazetidin-3-amine hydrochloride

Similarity: 0.79

Chemical Structure| 40320-60-3

[ 40320-60-3 ]

1-Benzhydrylazetidin-3-one

Similarity: 0.78

Chemical Structure| 1375303-15-3

[ 1375303-15-3 ]

2-(1-Benzhydrylazetidin-3-yl)propane-1,3-diol

Similarity: 0.77

Azetidines

Chemical Structure| 18621-17-5

[ 18621-17-5 ]

1-Benzhydrylazetidin-3-ol

Similarity: 0.98

Chemical Structure| 54881-13-9

[ 54881-13-9 ]

1-Benzylazetidin-3-ol

Similarity: 0.80

Chemical Structure| 1965305-27-4

[ 1965305-27-4 ]

1-Benzhydrylazetidin-3-amine hydrochloride

Similarity: 0.79

Chemical Structure| 40320-60-3

[ 40320-60-3 ]

1-Benzhydrylazetidin-3-one

Similarity: 0.78

Chemical Structure| 1375303-15-3

[ 1375303-15-3 ]

2-(1-Benzhydrylazetidin-3-yl)propane-1,3-diol

Similarity: 0.77